This technology could provide medical labs a quick, cost-effective way to diagnose methicillin-resistant Staphylococcus aureus
Even as in vitro diagnostics manufacturers are bringing rapid molecular tests to market that can identify infectious diseases within hours, a research collaboration involving a major university and a medical laboratory at an air force base has demonstrated the ability to identify antibiotic-resistant strains of Staphylococcus in just minutes.
This innovative research is being done by Auburn University’s College of Veterinary Medicine and clinical laboratory professionals at Keesler Air Force Base. Funding is by the U.S. Air Force. This research was of particular interest to the military because the risk for Staph infection increases when individuals are subjected to unhygienic conditions in close quarters. (more…)
Use of plasma technology will give healthcare workers another way to clean their hands
Even Buck Rogers and Flash Gordon would be amazed to learn that plasma technology is about to deliver a way for healthcare workers to sanitize their hands without using soap and water! Pathologists and clinical laboratory managers will be interested to learn about a novel device that bathes hands with plasma as a way to reduce the spread of microorganisms by healthcare workers, including superbugs like MRSA, an antibiotic-resistant strain of Staphylococcus aureus.
Prototypes already exist and are designed to be simple for healthcare workers to use. They would simply stick their hands into a small box that bathes the hands with plasma that is specifically engineered to zap bacteria, viruses and fungi. The plasma used in the hand sanitizer is a gas similar to that used in fluorescent lights, neon signs, and televisions, but works at room temperature and pressure.
Researchers say Mobidiag’s microarray-based diagnostic test technology looks promising
There’s a new DNA-based microarray platform that could speed identification of blood-borne pathogens. By allowing clinical laboratories to deliver test results in just 18 hours, use of this new microarray could improve early detection and management of sepsis patients.
In a study headed by Päivi Tissari, M.D., of the Division of Clinical Microbiology, Helsinki University Hospital Laboratory in Finland, the Prove-it sepsis assay, manufactured by Helsinki-based Mobidiag, demonstrated 94.7% clinical sensitivity, 98.8% specificity, along with 100% sensitivity and specificity for methicillin-resistant Staphylococcus aureus bacteremia. The conventional process of growing a culture—the medical laboratory’s gold standard—typically takes between one to three days to become positive and two more days to identify the bacteria and their antibiotic sensitivity patterns. Mobidiag’s Prove-it sepsis assay returns results in only 18 hours.
As more attention is paid to reducing the number of healthcare-associated infections (HIAs), hospitals and health systems respond with proactive programs to eliminate many obvious sources of such infections. In turn, this affects hospital laboratories, since they play a key role in every hospital’s infection control program.
The basic statistics are stunning. Hospital-acquired infections (HIAs) affect nearly 2 million Americans annually, resulting in 90,000 deaths and up to $6.5 billion in extra costs, according to the Centers for Disease Control (CDC).